Voyager Therapeutics (NASDAQ:VYGR) outlined what CEO Al Sandrock described as three “pillars of value” for the year ahead during a discussion at Oppenheimer’s 36th Annual Life Science Conference, ...

Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, today ...

Joseph La Barge has been mulling over the limitations of gene therapy for some time. So, when he left his position at Spark Therapeutics, having watched the company grow from its start in borrowed ...

CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for serious ...

A novel bioengineering strategy utilizing peptide display technology on the AAV1 capsid has successfully generated next-generation viral vectors with ...

(RTTNews) - Voyager Therapeutics, Inc. (VYGR), a developer of adeno-associated virus or AAV capsids, announced Tuesday a license option agreement, under which Novartis (NVS) will receive ...

With its lead gene therapy programs stalled by a series of setbacks, Voyager Therapeutics has been talking for months about refocusing its business on internal technology that finds capsids—the ...

Novartis has already commercialized a gene therapy that targets the central nervous system, but the pharmaceutical giant has more CNS gene therapies in its pipeline and it’s looking to improve the way ...

The possibilities for gene therapies are being realized as candidates come to market with hundreds more in development. Adeno-associated virus (AAV) is a common vector, yet current production, ...

Ginkgo Bioworks doesn’t want the biotech industry’s therapies. But it does want the platforms that create them, which is why the cell programming company is buying up StrideBio for its gene therapy ...

NORWICH, England & CHICAGO--(BUSINESS WIRE)--Ikarovec Ltd, which is developing dual-pathway gene therapies for vision-threatening retinal diseases, and VectorBuilder, a global leader in gene delivery ...

WALTHAM, Mass.--(BUSINESS WIRE)--Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies ...